46th week of 2009 patent applcation highlights part 33 |
Patent application number | Title | Published |
20090280132 | COUPLING OF PERIPHERAL TOLERANCE TO ENDOGENOUS IL-10 PROMOTES EFFECTIVE MODULATION OF T CELLS AND AMELIORATES AUTOIMMUNE DISEASE - Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor agonist or antagonist. The compounds and compositions of the invention may be used to selectively suppress the immune system to treat symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune disorders including autoimmune diabetes, rheumatoid arthritis and multiple sclerosis. | 2009-11-12 |
20090280133 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF - Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. | 2009-11-12 |
20090280134 | COMPOSITIONS AND METHODS FOR INHIBITING TOXIN A FROM CLOSTRIDIUM DIFFICILE - The present invention provides compositions and methods for treating or preventing infection by Toxin A producing bacteria. | 2009-11-12 |
20090280135 | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, to treat or prevent autoimmune or neurodegenerative diseases, to protect axons, and to prevent or reverse demyelination. | 2009-11-12 |
20090280136 | IMMUNIZATION OF FISH WITH PLANT-EXPRESSED RECOMBINANT PROTEINS - Plants are produced that express an amino acid sequence that, when administered to a fish, produce an antigenic or immune response in the fish. The amino acid sequence in one embodiment is an antigen from an organism that causes pathology in fish. The plant tissue may be fed to the fish, or mixed with other materials and fed to fish, or extracted and administered to the fish. | 2009-11-12 |
20090280137 | Methods, Compositions, and Sequences of ZP-Binding Peptides for Immunocontraception of Dogs and Other Animals - Disclosed are methods, compositions, and zona pellucida binding peptides and polypeptides for use in immunocontraception of canines and other animals. The disclosed compositions may include pharmaceutical compositions. | 2009-11-12 |
20090280138 | PEPTIDE - The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their use in diagnosis and therapy of cancer. | 2009-11-12 |
20090280139 | Novel Norovirus Particle for Use as an Antiviral or Vaccine - Norovirus capsid protein monomers having only the P domain, and not the hinge or S domain, can assemble spontaneously into an icosahedral form herein called the P-particle. Factors affecting the formation and stability of the P-particle, as well as providing methods for diagnosing and treating Norovirus-infected individuals and creating a vaccine for prevention of Norovirus infection are presented. | 2009-11-12 |
20090280140 | Early detection of mycobacterial disease using peptides - A number of protein and glycoprotein antigens secreted by | 2009-11-12 |
20090280141 | Streptococcal Genes - Peptides derived from | 2009-11-12 |
20090280142 | METHODS OF DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS - A method of detecting osteoporosis in a mammalian is disclosed herein which includes:
| 2009-11-12 |
20090280143 | GENETIC ADJUVANTS FOR IMMUNOTHERAPY - The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ. | 2009-11-12 |
20090280144 | Recombinant newcastle disease virus RNA expression systems and vaccines - This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I. | 2009-11-12 |
20090280145 | Adjuvant viral particle - The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine. | 2009-11-12 |
20090280146 | CONTROL OF INTESTINAL INFLAMMATORY SYNDROMES WITH A PREPARATION OF KILLED OR NON INFECTIOUS BACTERIA - This invention relates to the use of a preparation of killed or non infectious Gram positive bacteria such as Gram positive facultative intracellular bacteria, for example mycobacteria, for the treatment of intestinal inflammatory syndromes such as Crohn's disease or ulcerative colitis. | 2009-11-12 |
20090280147 | Compositions comprising dye-loaded particles - According to the invention, a cosmetic composition is provided comprising: | 2009-11-12 |
20090280148 | CASEIN NANOPARTICLE - An object of the present invention to provide: a nanoparticle, which can be produced without the use of surfactants and synthetic polymers, which has a controllable size and is stable in the acidic range, and which further contains an active substance; and a method for producing the same. The present invention provides a casein nanoparticle which contains an active substance and has an average particle size between 10 nm or more and less than 300 nm, which is produced by the following steps (a) to (c):
| 2009-11-12 |
20090280149 | Cosmetic and Method for Production Thereof - A cosmetic in an emulsified state, in which a titanium dioxide microparticle coated with hydrous silicic acid and/or a hydrous silicate compound, a higher alcohol, an oily component other than the higher alcohol, and a polysaccharide are contained, and the polysaccharide containing at least one of fucose, glucose, glucuronic acid and rhamnose as a constituent monosaccharide, and having fucose and/or rhamnose in a side chain is contained in an amount of 0.01% by weight to 1% by weight relative to the total amount of the cosmetic. And a cosmetic containing the higher alcohol, the oily component and the polysaccharide in an emulsified state, in which the higher alcohol is composed of two or more kinds of higher alcohols having different molecular weights, and is contained in the cosmetic in an amount of 1% by weight to 20% by weight relative to the total amount of the cosmetic. The oily component is contained in an amount of 1% by weight to 20% by weight relative to the total amount of the cosmetic, and the polysaccharide is contained in an amount of 0.01% by weight to 1% by weight relative to the total amount of the cosmetic, and a producing method thereof. | 2009-11-12 |
20090280150 | Targeted And Individualized Cosmetic Delivery - A system and methods are provided for targeted and individualized delivery of multiple skin benefit agents to the skin of a user. The image of a predetermined treatment area of the user's skin is first captured by an imaging device. The captured image data is then analyzed by a computing device to generate a unique skin profile for the user, which is indicative of the skin conditions at the predetermined treatment area. Based on such skin profile, a printing device prints out one or more cosmetic delivery sheets that can be applied to the predetermined treatment area. Each of the cosmetic delivery sheets contains a substrate with multiple isolated, discrete regions, while at least two of the regions are imprinted with different skin benefit agents for treating different skin conditions of the predetermined treatment area according to the unique skin profile of the user. Targeted delivery of one or multiple skin benefit agents to the skin of a user may be achieved by applying and conforming to the skin a flexible cosmetic delivery sheet having associated therewith, on a first surface, one or multiple cosmetic treatment compositions provided in isolated, discrete regions, while an opposite surface of the sheet is provided with imprinted, predetermined regions corresponding to respective isolated, discrete regions on the first surface of the sheet. The user manipulates the sheet at the imprinted predetermined regions in a manner indicated by the imprinted predetermined regions to release one or multiple skin treatment compositions from the isolated, discrete regions and deliver effective amounts of one or multiple skin benefit agents to the targeted areas of the skin underlying the isolated, discrete regions of the sheet. | 2009-11-12 |
20090280151 | FABRIC WITH ACTIVE PRINCIPLES AND RELEVANT RECHARGING METHOD OF THE ACTIVE PRINCIPLES - The fabric consists of lycra fibres and microfibres and it has long the fibres a glycoprotein ( | 2009-11-12 |
20090280152 | Tropoelastin for Promoting Endothelial Cell Adhesion or Migration - The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells. | 2009-11-12 |
20090280153 | TEXT NOT AVAILABLE - Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal. | 2009-11-12 |
20090280154 | Biodegradable Scaffold with ECM Material - We add discontinuous regions of Extra Cellular Matrix (ECM) to a biodegradable scaffold. Hereby it is possible to combine the range of physical properties the scaffold can offer with the reconstructive properties of the ECM. The optimal amount of discrete ECM material for each application is disclosed and this concentration is equally distributed in the dressing hence avoiding unnecessary high concentrations of ECM. In addition to the effect of the ECM, the porous structure of the base material provides the cells with a structure for in-growth. | 2009-11-12 |
20090280155 | Coating systems for the controlled delivery of hydrophilic bioactive agents - Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer. | 2009-11-12 |
20090280156 | BIOIMPLANT - To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 90% or less is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film. If necessary, a metal oxide layer made of a metal oxide having an isoelectric point of less than 7 is formed on the bioimplant thereby suppressing adhesion of bacteria. | 2009-11-12 |
20090280157 | Method of Modifying Materials Surfaces - The present invention relates to “grafting to” methods of modifying materials surfaces with high-density polymer brushes. A method of the present invention comprises contacting in succession or simultaneously an activated material surface, a solution of a polymeric material having a polymeric backbone with pendant reactive moieties, and a melt of brush-forming terminally-functionalized polymer chains, in order to allow a covalent bonding reaction to occur between surface and polymers, wherein upon completion of the reaction, the polymeric material forms a layer between the material surface and the brush polymer chains. | 2009-11-12 |
20090280158 | SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION - The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s). | 2009-11-12 |
20090280159 | PROCESS FOR MANUFACTURING CHEWABLE DOSAGE FORMS FOR DRUG DELIVERY AND PRODUCTS THEREOF - A palatable, soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the soft chews do not require the generation of heat during mixing of active and inactive ingredients, provide stable concentrations of the active ingredient, and produce chews of consistent weight and texture. | 2009-11-12 |
20090280160 | PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION - Pharmaceutical compositions comprising phenylephrine or a pharmaceutically acceptable salt thereof and methods for administering the pharmaceutical compositions wherein the composition is formulated for systemic absorption of phenylephrine that avoids first pass metabolism. The compositions of the invention are formulated to be applied to oral mucosa of an animal to allow for enhanced systemic delivery of therapeutically active form of phenylephrine. | 2009-11-12 |
20090280161 | Thin Film Multilocular Structure Made of Collagen, Member for Tissue Regeneration Containing The Same, and Method for Producing The Same - The present invention provides a new structure made of collagen for improving promotion of nerve tissue regeneration, curing and regeneration of a defective part of a soft biological tissue and so on without using laminin or nerve growth factor (NGF), and a member for tissue regeneration including the same. The structure made of collagen according to the present invention has a thin film multilocular formation and therefore a new structure different from a colloid form, a gel form, and a fiber form. Therefore, when the new structure made of collagen according to the present invention is used as a member for tissue regeneration, surprisingly, promotion of regeneration, shortening of a treatment period, functional recovery, or the like of bodily tissue such as nerve tissue, subdermal tissue, submucosal tissue, membranous tissue, fat tissue, muscle tissue, skin tissue, and gingival tissue can be improved. Furthermore, when the structure according to the present invention is used to a patient having neuropathic pain, the member has an effect on the disappearance of the pain. | 2009-11-12 |
20090280162 | LAYERED WOUND DRESSING - A wound dressing including at least one biocompatible support material and at least one polysaccharide as a hemostatic means (hemostyptic) and/or that unites severed regions of body tissue, and having a layered structure of at least one layer of the support material and at least one layer of the polysaccharide. | 2009-11-12 |
20090280163 | High-Efficiency Fusogenic Vesicles, Methods of Producing Them, and Pharmaceutical Compositions Containing Them - The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetic agents to cells and tissues. | 2009-11-12 |
20090280164 | THERAPY FOR HUMAN CANCERS USING CISPLATIN AND OTHER DRUGS OR GENES ENCAPSULATED INTO LIPOSOMES - A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir. | 2009-11-12 |
20090280165 | COMPOUNDS THAT BIND ALPHA5BETA1 INTEGRIN AND METHODS OF USE - The present invention provides biologically active compounds that bind an αsβi integrin. Also included in the present invention are methods for using such biologically active compounds. | 2009-11-12 |
20090280166 | FERRITIN AS A THERAPEUTIC TARGET IN ABNORMAL CELLS - Compositions for treatment of iron related diseases comprise an inhibitor of ferritin. An inhibitor of ferritin is active to reduce the level of H ferritin protein in a cell and/or to reduce the activity of H ferritin in a cell. Compositions providing cytoprotection, regulation of iron, increasing longevity and viability of cells are described. | 2009-11-12 |
20090280167 | ENHANCEMENT OF DRUG THERAPY BY MIRNA - This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for predicting response to therapy not limited to therapeutic agents is also disclosed. A method for the identification and therapeutic application of small molecules which are modulators of these nucleic acids are also included in this application | 2009-11-12 |
20090280168 | CHLAMYDIA OMP ANTIGEN - The present invention provides purified and isolated polynucleotide molecules that encode | 2009-11-12 |
20090280169 | Compositions of peptides and processes of preparation thereof - The present invention provides composition of comprising a therapeutically effective amount of at least one peptide, polypeptide, analog or derivative thereof and a sufficient amount of at least one stabilizing agent to improve the stability of the peptide, polypeptide, an analog or derivative thereof, wherein at least one stabilizing agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. The method for preparation of a composition of a peptide, polypeptide, protein, an analog and/or derivative thereof is also provided. The process comprises mixing the peptide, polypeptide, protein, an analog or derivative thereof with a sufficient amount of at least one stabilizing agents to improve the stability of the peptide, polypeptide, protein, an analog or derivative thereof, and the agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. | 2009-11-12 |
20090280170 | Compositions of GnRH related compounds and processes of preparation - The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. | 2009-11-12 |
20090280171 | METHOD OF TREATMENT WITH PREDICTABLY BREAKABLE PHARMACEUTICAL TABLETS - The invention involves the use of finished dosage forms, e.g., tablets, by breaking or otherwise dividing them to produce a predictably accurate smaller or lower dose. | 2009-11-12 |
20090280172 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a dosage form for transmucosal administration comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and an excipient for transmucosal delivery, wherein the active ingredient is present in an amount of 0.001 to 80% by weight based on the total weight of the dosage form. | 2009-11-12 |
20090280173 | Multilayer Omeprazole Tablets - Multilayer tablets of Omeprazole and/or a salt thereof essentially bioequivalent in terms of plasma Omeprazole C | 2009-11-12 |
20090280174 | Solid Pharmaceutical Preparation - It is intended to provide a long-acting solid pharmaceutical preparation which has an immediate release part and a sustained release part containing tramadol or a pharmaceutically acceptable salt thereof, is fast-acting and stably has an excellent release property showing little pH dependency in the initial elution. The invention relates to a long-acting solid pharmaceutical preparation characterized by having an immediate release part and a sustained release part, containing tramadol or a pharmaceutically acceptable salt thereof as an active ingredient in both parts and containing partially pregelatinized starch and an excipient as additives in the immediate release part. The preparation of the invention is a long-acting preparation in which an effective blood concentration is reached rapidly after taking it for rapid pain-relief and a drug action can be sustained for a long time thereafter and is practical as a preparation showing a stable, pH-independent and rapid initial elution behavior and, further, having a sufficient hardness enough to meet the need for avoidance of defacement, cracking, chipping, etc. during tablet coating. | 2009-11-12 |
20090280175 | Multilayer Proton Pump Inhibitor Tablets - Multilayer tablets of a proton pump inhibitor essentially bioequivalent in terms of plasma C | 2009-11-12 |
20090280176 | CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM - A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided. | 2009-11-12 |
20090280177 | Pharmaceutical preparation for treating fibromyalgia - It is difficult to develop pharmaceutical agents for treating fibromyalgia since both the pathogenetic cause and the onset mechanism remain to be clarified. An antirheumatic agent salazosulfapyridine was administered to fibromyalgia patients. Unexpectedly, salazosulfapyridine was seen to be effective in fibromyalgia patients in whom neither the rheumatoid factor nor an immune disorder was detectable, in particular to relieve pain of enthesitis. Furthermore, salazosulfapyridine was also effective to alleviate enthesitis and to relieve pain in fibromyalgia. In addition, the combined use of salazosulfapyridine with a corticosteroid or a nonsteroidal anti-inflammatory agent potentiated the therapeutic effect of salazosulfapyridine in clinical patients to whom salazosulfapyridine alone was not effective enough. | 2009-11-12 |
20090280178 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof - Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation. | 2009-11-12 |
20090280179 | Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material - A resorbable bone replacement material made of calcium phosphate particles of different phases which are embedded in an inventive-specific cross-linked collagen matrix. The goal is to form a non-brittle, bone replacement moulded body having a positive fit, i.e. having a shape which is anatomic and/or corresponds to the defect, which perfectly fills the bone defect and can be resorbed thereby. Said goal is achieved by producing the bone replacement material made of a mixture of calcium phosphate particles which is embedded in an inventive cross-linked collagen matrix. In particular, the collagen cross-linking is achieved by a Laccase-induced peptide cross-linking and suitable bridge molecules. Essentially substituted dihydroxyarmotes and/or substrates of the lignolytic polyphenoloxidases, such as Laccases, are suitable as bridge molecules. Also, monocyclic ortho-dihydroxyaromates, monocyclic para-dihydroxyaromates, bicyclic monohydroxyaromates, polycyclic monohydroxyaromates, bicyclic dihydroxyaromates, polycyclic dihydroxyaromates, bicyclic trihydroxyaromates, polycyclic trihydroxyaromates, or mixtures thereof are used. The inventive hydroxyaromates are not part of a polymer chain as opposed to the known conchal adhesive. | 2009-11-12 |
20090280180 | COLLAGEN-BASED MATRICES WITH STEM CELLS - Collagen based-matrices and methods of their use are described. More particularly, collagen-based matrices for differentiating stem cells and progenitor cells, and for producing and isolating blood vessels and vascularized graft constructs are described. | 2009-11-12 |
20090280181 | DELIVERY OF NUCLEIC ACID COMPLEXES FROM PARTICLES - Embodiments of the invention include particles with nucleic acid complexes, medical devices including the same and related methods. In an embodiment, the invention can include a method of making a medical device. The method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, adsorbing the nucleic acid complexes to porous particles to form nucleic acid complex containing particles, mixing the nucleic acid complex containing particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, combining the nucleic acid complexes with a material to form nucleic acid complex containing particles in situ, mixing the nucleic acid complex particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the invention can include an implantable medical device including a substrate, an elution control matrix disposed on the substrate; a plurality of particles disposed within the elution control matrix, and a plurality of nucleic acid complexes disposed within the particles, the nucleic acid complexes comprising a nucleic acid and a cationic carrier agent. Other embodiments are included herein. | 2009-11-12 |
20090280182 | Devices for the treatment of wounds and methods and kits therefor - Interpenetrating network hydrogels are described that may be incorporated into wound dressings and/or in implants. The properties of the interpenetrating network hydrogel may be tuned to control an amount of moisture in a wound environment. The devices, methods, and kits described herein may be adapted to treat a variety of wound types at a variety of healing stages over a range of time scales. Some hydrogels may be configured to deliver one or more vulnerary agents to a wound. The interpenetrating network hydrogels may also be adapted to control a rate and/or amount of moisture uptake so that the hydrogels may be used as expandable implants to expand tissue. | 2009-11-12 |
20090280183 | MULTIPARTICULATE FORM OF ADMINISTRATION, COMPRISING NUCLEIC ACID-CONTAINING MUCOADHESIVE ACTIVE INGREDIENTS, AND METHOD FOR PRODUCING SAID FORM OF ADMINISTRATION - The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients. | 2009-11-12 |
20090280184 | PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND METHODS OF TREATING ACHES/PAINS - Provided are methods and compositions useful for treating/aches and/or pains. The compositions comprise an herbal therapeutic agent and an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane. | 2009-11-12 |
20090280185 | Particulate wood preservative and method for producing the same - A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 μm, 0.2 μm, or 0.15 μm. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper based particles of the invention. | 2009-11-12 |
20090280186 | PROCESS FOR PRODUCING SPHERICAL BASE GRANULE COMPRISING EASILY WATER-SOLUBLE DRUG - Provided is a process for producing spherical base granules comprising a easily water-soluble drug and suited for film coating by spraying a layering liquid over pharmaceutically inert spherical core particles, thereby coating the particles with a layer comprising the easily water-soluble drug, wherein (1) the spherical core particles have a microcrystalline cellulose content of 30 mass % or greater and a water absorbing capacity of 0.5 cm | 2009-11-12 |
20090280187 | Oxidation-Stable Granulate Containing Unsaturated Fatty Acids - One aspect of the invention relates to a water-dispersible granulate having a mass weighted average diameter of at least 100 m, said granulate comprising: 40-90 wt. % of carbohydrates; 2-30 wt. % of lipids containing at least 1% unsaturated fatty acids by weight of the granulate and at least 30 mg/kg of a pro-oxidative metal selected from the group consisting of iron, copper and combinations thereof; wherein at least 50 wt. % of the lipids is present as non-dispersed lipids. Despite the fact that the present granulate contains a substantial amount of unsaturated fatty acids as well as a high level of iron and/or copper, said granulate is nonetheless very stable against oxidation. The granulate of the present invention is easy to manufacture by a process that does not employ emulsification or pro-oxidative conditions. The present invention also provides a process for the manufacture of the aforementioned granulate. | 2009-11-12 |
20090280188 | ASYMMETRIC FUNCTIONALIZATED NANOPARTICLES AND METHODS OF USE - Disclosed herein are asymmetrically functionalized nanoparticles. Further disclosed herein are methods of preparing asymmetrically functionalized nanoparticles. Asymmetrically functionalized nanoparticles can be used in various therapeutic methods. | 2009-11-12 |
20090280189 | System for the liberation of an active principle and its use - A local system for the liberation of an active principle is described which consists of spherical bodies which are composed of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate and, if necessary, zirconium dioxide and/or barium sulphate and a pharmaceutical active principle, which contains at least one hemostyptically effective compound stable at least up to 120° C., preferably a calcium salt. The local system for the liberation of an active principle is provided as medical product or drug. | 2009-11-12 |
20090280190 | ANTI-ANGIOGENIC PEPTIDES FROM THE N-TERMINUS OF ENDOSTATIN - Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis. | 2009-11-12 |
20090280191 | PREVENTIVE REMEDIAL THERAPEUTIC AGENT FOR PHOSPHORUS IMPAIRMENT, ORAL AGENT FOR ADSORBING PHOSPHATE ION CONTAINED IN FOOD, BEVERAGE AND CHEMICAL, AND PROCESS FOR PRODUCING THEM - The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present. | 2009-11-12 |
20090280192 | METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE - Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of an agent which reduces serum insulin levels. | 2009-11-12 |
20090280193 | Enerceutical mediated activation of the Alternative Cellular Energy (ACE) pathway in the therapy of diseases - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; or other activating components, such as magnesium chloride; with the combined mixture being put into a UV transparent container, such as a plastic bag, or placed on some other material, which can be laid onto the skin and illuminated with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients' skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases including illnesses attributed to infections with stealth adapted and conventional viruses and diseases attributed to an inadequacy of the mitochondria and associated metabolic pathways, including states of hypoxia and nutritional deficiencies. | 2009-11-12 |
20090280194 | USE OF NITROXYL (HNO) FOR THE TREATMENT OF CANCERS OVEREXPRESSING MAT-8 - Compositions and methods for treating hormone dependent or independent cancers overexpressing MAT-8 in a patient by administration of nitroxyl-donating compounds and treating patient suffering from cancers such as prostate cancer, breast cancer, pancreatic cancer, colon cancer and lung cancer. | 2009-11-12 |
20090280195 | Methods for the treatment of addictive disease and addiction to chemical substances and addictive behaviors using a formula containing the following formulation: Mucuna pruiens, N Acetyl L Cysteine, Magnesium Citrate - The invention is directed at the formulation of | 2009-11-12 |
20090280196 | CISSUS QUADRANGULARIS PLANT EXTRACTS FOR TREATING OSTEOPOROSIS AND THE EXTRACTION PROCESS THEREOF - The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of | 2009-11-12 |
20090280197 | CELL ACTIVATOR, COLLAGEN PRODUCTION PROMOTER, SKIN WHITENING AGENT, ANTIOXIDANT AGENT, ANTIINFLAMMATORY AGENT, AROMATASE ACTIVITY PROMOTER, PROTEASE ACTIVITY PROMOTER, EXTERNAL PREPARATION FOR SKIN, AND FOOD - The present invention provides a cell activation agent, a collagen production accelerator, a whitening agent, an antioxidant, an anti-inflammatory agent, an aromatase activity accelerator, a protease activity accelerator, a skin external preparation, and food, which all contain an extract of | 2009-11-12 |
20090280198 | Combined effects of nutrients on proliferation of stem cells - A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements. | 2009-11-12 |
20090280199 | Neuroprotective Compositions and Methods of Using Same - The present invention provides compositions and methods for preconditioning, providing neuroprotection to, and/or enhancing the neural recovery of an individual. The compositions include pomegranate extract, blueberry extract, curcumin and/or magnesium citrate, and Omega 3 fatty acids. The compositions can be used in beverages or food products. In preferred embodiments, the compositions are a component of an aqueous beverage, i.e. an energy, sports, or soft drink. | 2009-11-12 |
20090280200 | HERBAL EXTRACTS WHICH INDUCE IMMUNE CELLS TO PRODUCE INTERFERON AND ACTIVATE TOLL-LIKE RECEPTORS - An herbal extract which induces immune cells to produce interferon and activates Toll-like receptors and a preparation method thereof are provided. The herbal extract is extracted from an effective amount of raw material including Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix. Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5:1-5:1-5:1-3:1-3. | 2009-11-12 |
20090280201 | NATURAL EXTRACT FOR THE CONTROL OF BOTRYTIS CINEREA AT PRE- AND POST-HARVEST - Obtaining, producing and using metabolites having anti-botrytis cinerea properties from a natural extract of a native Chilean plant. An in vitro cultivated quillay extract ( | 2009-11-12 |
20090280202 | Extracts of Aristolochia Longa pomer and uses thereof - Methods of extracting from a part of a variety of the species | 2009-11-12 |
20090280203 | COMPOSITIONS OF ATOMIZED OR LYOPHILIZED MACA (Lepidium meyenii) EXTRACTS AND ATOMIZED OR LYOPHILIZED YACON (Smallanthus sanchifolius) EXTRACTS AS ADJUVANTS IN THE TREATMENT OF DIFFERENT CONDITIONS - The present invention refers to compositions of atomized or lyophilized extracts of selected maca hypocotyls of the red and black variety and atomized or lyophilized parts of the yacon plant selected from leaves and roots. The invention also refers to the methods to prepare such compositions using aqueous or hydroalcoholic extraction processes. Likewise, as novel element of the maca hypocotyls extraction process is the selection of the batches of maca hypocotyls having a pH of less than 5.5, which have better biological activity than those with a greater pH. The compositions of the invention are useful in the treatment of different conditions and diseases. | 2009-11-12 |
20090280204 | USE OF EXTRACTS OF CAPRARIA BIFLORA IN THE PREVENTION AND/OR TREATMENT OF SENILE CATARACTS - The invention provides methods for treating and/or preventing the recurrence of a senile cataract, and/or for inhibiting the development of a senile cataract and/or an incipient senile cataract, in a human or animal subject. The invention further provides nutraceutical compositions suited for the same, derived from an extract of the plant | 2009-11-12 |
20090280205 | CO-EXTRUDER HAVING A FILLING ENTRANCE FROM THE REAR - A cutter assembly for an extruder includes an elongated extrusion member having an open feed end. The open feed end is attachable in fluid communication with the extruder for supplying a mash to said elongated extrusion member. An extrusion die is supported on a front of the elongated extrusion member. The extrusion die includes an extrusion outlet formed therein. A filling tube is mounted on a rear of the elongated extrusion member and is attachable in fluid communication with the extruder for supplying a filling to the filling tube. A cutter member has a drivable end and a cutter blade with a cutting surface for cutting extrudate to a desired length as the extrudate exits the extrusion die. The cutter member is operably connectable at the drivable end to a drive device of the extruder for reciprocatably sliding the cutting surface of the cutter blade over and away from the outlet of the extrusion die. | 2009-11-12 |
20090280206 | MACHINE FOR BLOW-MOULDING CONTAINERS FROM EXTRUDED PARISONS - The invention describes a machine typically comprising two or four carriages with associated mould/counter-mould (S | 2009-11-12 |
20090280207 | SUPERFINE FIBER CREATING SPINNERET AND USES THEREOF - Apparatuses and methods for the production of superfine fibers. | 2009-11-12 |
20090280208 | Mold and method for manufacturing mold - Rough machining is performed onto a surface of a base material of a mold. Next, a covering layer whose maximum degree of roughness Ry is 5 to 20 μm is formed on the surface onto which the rough machining has been performed. | 2009-11-12 |
20090280209 | Injection moulding device comprising needle valve nozzles in a back-to-back arrangement - The present invention relates to injection molding apparatus ( | 2009-11-12 |
20090280210 | Milk production method - A method for improving the half-life of milk comprising the step of: a) contacting milk with an antibody raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the half-life of milk; ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the half-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk. | 2009-11-12 |
20090280211 | METHOD OF PREPARING A FOOD PRODUCT - A method of preparing a food product includes providing a high-intensity sweetener selected from the group consisting of acesulfame-K, sucralose, glycyrrhizinate, dihydrochalcones, monellin, inonatin and mixtures thereof. A binder selected from the group consisting of aluminosilicates, polyvinyl acetate, polyols, silica, monioglycerides, waxes and mixtures thereof is provided. The binder and the high-intensity sweetener are compacted in a roll compactor to form a compacted mixture. The compacted mixture is added to a food product. In one embodiment, a chewing gum composition includes gum base; bulk sweetener; flavor and the compacted mixture. | 2009-11-12 |
20090280212 | METHOD OF PRODUCING FILAMENTOUS FUNGUS CULTURE PRODUCT - It is an object of the present invention to provide a method of adjusting productivity of enzymes, in particular, amylolytic enzymes, plant fiber degradation enzymes and proteolytic enzymes in a filamentous fungus culture product, by controlling releasing rate of nutrients from the culture raw material into the culture system when a filamentous fungus culture product is produced by culturing filamentous fungi in liquid medium containing as the culture raw material at least one selected from the group consisting of cereals, beans, tubers, | 2009-11-12 |
20090280213 | Production and use of Anka-polyphenol containing broth - The present invention is related to a process for producing an Anka-polyphenol containing broth with high antioxidant activity, comprising saccharifying and then fermenting raw rice with a | 2009-11-12 |
20090280214 | ARTIFICIAL INTELLIGENCE APPARATUS FOR MAKING FROZEN YOGURT AND METHOD FOR CONTROLLING - An apparatus includes a housing, a heat conductive container for receiving yogurt ingredients, a heating unit installed in the housing and provided with a heating element for heating the container, a cooling unit installed in the housing and provided with a refrigerant pipe for cooling the container by a refrigeration cycle caused by supplying electric power, a stirring unit provided with a stirring blade which is driven by a motor to be rotated in the container, and a control unit configured to selectively control the heating unit, the cooling unit and the stirring unit to make frozen yogurt of the yogurt ingredients. A method includes steps for preparing frozen yogurt using the apparatus, wherein the frozen yogurt is fermented, ripened and frozen under control of the control unit within a single container, for example. In alternative examples, other fermented yogurt and non-fermented ice cream or sherbet products are made using the same apparatus. | 2009-11-12 |
20090280215 | METHOD OF ENZYMATICALLY TREATING GREEN TEA LEAVES - It is to provide a method for producing a rich-flavored green tea extract liquid by converting the ingredients by performing enzymatic treatment to raw material green tea leaves in order to improve the quality of green tea leaves and extracting the tea leaves. A green tea extract liquid with excellent flavor is produced by mixing and allowing to react ground green tea leaves, made by grinding dried green tea leaves or ground green tea leaves which have been ground during green tea manufacture process, with an enzyme solution at a weight ratio of 1:0.2 to 1:5, and then extracting with water or warm water. By performing enzymatic reaction according to the method of the present invention, the reaction can proceed dramatically, and it is possible to convert effectively the flavor ingredients by an enzymatic treatment of raw material tea leaves, which was difficult in a conventional method, and a rich-flavored green tea extract liquid with an excellent flavor can be produced by extracting the tea leaves. | 2009-11-12 |
20090280216 | Pet snack food and production method thereof - In some preferred embodiments, a pet snack food, which is excellent in eating preference and low in risk of causing health impairment for pets due to excessive consumption of nutrition even if it is given in somewhat large amounts as a snack in addition to regular feeding, is provided. The pet snack food is a mixed composition including starch and animal protein as essential ingredients, and preferably further including optional ingredients such as minerals, vitamins, yeasts, and dietary fibers. It is preferable that the pet snack food is a bulky formed product having a foaming ratio of 3 to 20 formed by bulk-foaming extrusion using an extruder. | 2009-11-12 |
20090280217 | Method for Production of Soybean Peptide Mixture - The object is to provide a soybean protein hydrolyzate which can be produced by hydrolysis of a soybean protein produced by “method B” as defined in the description and produces no dreg even when refrigerated under acidic conditions, particularly a soybean peptide mixture having a relatively low molecular weight. Disclosed is a method for production of a soybean peptide mixture, comprising the steps of: (a) extracting a concentrated soybean protein with water to yield an extract; (b) treating the extract with a protease under alkaline to neutral conditions; (c) further treating the resulting product with a protease under acidic conditions; (d) treating the resulting product with a phytic acid (phytase)-decomposing enzyme; and (e) separating and removing an insoluble material from the product. | 2009-11-12 |
20090280218 | PROCEDURE TO OBTAIN WHOLEGRAIN FOOD FOR RUMIANTS - It comprises a 2nd step of selected cereals grinding and a 3rd step of mixing of the grinded cereal with minerals, pellets and fiber for between 3 and 7 minutes until obtaining an homogenous mass. The process also includes a 4th step where a fat component is added, and a 6th step where a protein source is added. It also comprises an 8th step of drying of the obtained wholegrain pieces with hot air and a 9th step of adding a liquid cover which adds a non proteic nitrogen source and amino acids. The final steps of the procedure consist of a 10th step of adding a solid cover which includes antibiotics and minerals and an 11th step of cooling with cold air blowing of the wholegrain food pieces in order to obtain a final product with a temperature which cannot exceede room temperature in more than 5° C. and a residual humidity which cannot exceede the 11%. | 2009-11-12 |
20090280219 | CAPSULE WITH SEALING MEANS - A capsule ( | 2009-11-12 |
20090280220 | Relatively humid food for animals with combined ingredients for instantaneous preparation system - Food Relatively Humid For Animals With Ingredients Combined For Instantaneous Preparation System, establishing a more affective relationship between the pet and its owner, through an animal food that is close to human food in terms of preparation, aspect and flavor, keeping, however, the nutritional characteristics of animal food necessary to the animal's health, through a combination of components such as protein and/or vegetable particles (feed) or pasta and other extruded particles—obtained by extrusion and/or co-extrusion processes, with balanced nutrients, allied to the complement of meat and vegetables—obtained by dehydration processes. Such combination is obtained following an ideal relation of humidity/water activity obtained through processing, keeping the food preserved in its adequate nutritional and humidity characteristics, for long periods of time, for packaging in packages such as jars, boxes, bags and others, vacuum-sealed or not. After the assembly (mixture) of these elements, a humid animal food with the nutritional ingredients necessary to health is formed, and that, from its packaging until its ingestion, is similar to the procedures for the preparation of human food. | 2009-11-12 |
20090280221 | Vegetable casing film and method for production of tubular sausage casings - Tubular sausage casings can be prepared from non-animal materials, primarily starches and flours by film-casting followed by gluing with an edible glue composed of konjac and carrageenan. In this way, it has been made possible to prepare non-animal meat casings commercially, that can be used with conventional sausage production technology. | 2009-11-12 |
20090280222 | TUNNEL PASTEURIZER - A tunnel pasteurizer having a tunnel, through which the material to be pasteurized is conducted and sprayed or sprinkled with water, and with a trap region for the draining water arranged on the bottom of the tunnel, pasteurizer and a plurality of temperature zones arranged in the transport direction, and the trap region is divided into separate trap zones which correspond to the temperature zones, from which the water is re-supplied to the respective tunnel zones, and comprising a control means for controlling the water temperature in the temperature zones. To improve control of the temperature in the individual temperature zones, the control and the tubing of the trap zones is adapted such that water can selectively be taken from the individual trap zones for temperature control and can selectively be returned to other temperature zones, wherein water is buffered in the individual temperature zones separate from other temperature zones in a respective zone buffer. | 2009-11-12 |
20090280223 | Produce Treatment Method - A method for storing fresh produce and comestible derivatives thereof while controlling the total viability count and/or surface pathogen count thereon comprises the step of shining light wavelengths selected from blue light, red light or a combination of red light and blue light onto the surface of the produce. | 2009-11-12 |
20090280224 | PROCESS FOR PRODUCING BAKED POTATO SLICES WITH EXPANDED TEXTURE - A method is disclosed for producing a baked snack chip made from a raw potato slice. The snack chip has a light, crispy, expanded texture similar to the texture of a fried potato chip. It is formed by compressing and heating a partially dried potato slice and then expanding the potato slice. Alternatively, the expanded potato slice is compressed again. | 2009-11-12 |
20090280225 | Process of Making Puff Pastry - The inventive process relates to making flour confectionery products, namely, puff pastry, and comprises: preparation of dough with certain humidity by mixing flour, water, citric acid, and egg products, maturing the dough for swelling of gluten, forming the dough by rolling it out in several stages, applying at the last stage a cover layer with filler having thickness not exceeding 2 mm, sandwiching the dough with soft-fat component, multiple rolling and cooling the dough in several stages, forming dough pieces, covering each piece with the cover layer, baking the dough at a temperature of 240° C., the humidity of the dough is maintained within the range of 22-27%. The filler may have different bases: grated cheese, salt, spices, mushrooms, nuts, invert liquid sugar with spices or dried fruits or poppy-seeds or sesame, or combinations thereof. The resultant products have high organoleptic qualities and preserve their consumer qualities within a long time period. | 2009-11-12 |
20090280226 | Method For Processing Edible Animal Products - Processing apparatus and method for meat, poultry and fish products include multiple successive immersions in sanitizing solutions at different temperatures within controlled environments including exposures to fluids at pressures different from ambient pressure to reduce resident microbial contaminants in preparation for packaging and distribution. | 2009-11-12 |
20090280227 | METHOD FOR PRODUCING MOLDED FOOD ITEMS FROM INDIVIDUAL PIECES OF VEGETABLES, MEAT OR OTHER FOOD - A method for producing ready-to-prepare molded food items, the method including combining a first food item and a second food item to form frozen starting products having frozen individual pieces and introducing the frozen starting products continuously or in batches into at least one mold cavity. The method further including molding the frozen starting products to form a ready-to-prepare frozen end product by compacting the frozen starting products located in the at least one mold cavity so as to mold the ready-to-prepare food items. | 2009-11-12 |
20090280228 | BEVERAGE STIRRING DEVICE - A beverage stirring device comprising:
| 2009-11-12 |
20090280229 | METHOD AND APPARATUS FOR MANUFACTURING PROTEIN BEVERAGES - An apparatus for hot filling containers with protein beverage may comprise a batch tank adapted for receiving a protein beverage, a first heat exchanger adapted for heating the protein beverage to a pasteurizing temperature, a reservoir adapted for receiving the protein beverage and having an overflow stream of the protein beverage, a filler adapted for at least partially filling containers with the protein beverage, a second heat exchanger adapted for cooling the overflow stream, a rework tank adapted for receiving the overflow stream, and a control valve adapted for controlling a percentage of the overflow stream recycled to the first heat exchanger from the rework tank such that the protein beverage remains substantially free of floc. A method for making a protein beverage substantially free of floc is also described. | 2009-11-12 |
20090280230 | COMESTIBLE COMPOSITIONS COMPRISING HIGH POTENCY SAVORY FLAVORANTS, AND PROCESSES FOR PRODUCING THEM - The present invention relates to the use of certain high potency savory (“umami”) taste modifiers, as savory flavoring agents and/or enhancers of monosodium glutamate, for the preparation of foods, beverages, and other comestible compositions, and to processes for preparing food flavorant compositions for use in the preparation of comestible food and drink. | 2009-11-12 |
20090280231 | PRO-OXIDANT SUGARS BALANCED WITH POLYPHENOLIC ANTIOXIDANTS - A dry edible sugar-based sweetener composition in the form of a granular or powdered material containing a first quantity of at least one natural sugar combined with a second quantity of polyphenolic antioxidants (aka phenolic antioxidants, measured as gallic acid equivalents). The phenolic antioxidants are provided by at least one dry water-soluble extract purified from edible fruit and/or vegetable material, in which the ratio of the second quantity to the first quantity is preferably between 0.5% and 10% by weight. | 2009-11-12 |